Trial Profile
A study to investigate the effect of belimumab on B cell signature profile in patients with systemic lupus erythematosus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Biomarker; Pharmacodynamics
- 11 Feb 2016 New trial record